# Efficacy of Silexan in anxious patients

Submission date	Recruitment status	[X] Prospectively registered
04/10/2012	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
26/10/2012	Completed	Results
Last Edited	Condition category	Individual participant data
26/10/2012	Mental and Behavioural Disorders	<ul><li>Record updated in last year</li></ul>

### Plain English summary of protocol

Background and study aims:

Silexan is an essential oil produced from fresh Lavandula angustifolia flowers. The objective of the study is to show that Silexan is effective and safe in treating mixed anxiety and depression, where the main symptoms are low mood, prominent anxiety, loss of interest with associated symptoms, restlessness and tension and disturbed sleep.

#### Who can participate?

Adult male and female patients (aged 18 65 years) with symptoms of anxiety and depression. What does the study involve?

One group of the patients will receive Silexan for 10 weeks. The other group will take a placebo (dummy) instead. During the study the severity of the symptoms of the disease will be measured using established scales. The scales are either self-reported or will be assessed by a trained assessor.

What are the possible benefits and risks of participating?

The participants who receive verum can expect an improvement of their symptoms of anxiety and depression. There are no know risks of using lavender oil active ingredients.

Where is the study run from?

From about 30 medical centres in Germany.

When is the study starting and how long is it expected to run for?

The study will start in October 2012 and will run for about 15 months until the required number of 300 patients have been recruited and treated.

Who is funding the study?

Dr. Willmar Schwabe GmbH & Co. KG, Germany

Who is the main contact?
Dr. Stephan Klement
Stephan.klement@schwabe.de

# **Contact information**

Type(s)

#### Scientific

#### Contact name

Prof Hans-Peter Volz

#### Contact details

Bezirk Unterfranken Balthasar-Neumann-Platz 1 Werneck Germany 97444

# Additional identifiers

#### Protocol serial number

750201.01.035

# Study information

#### Scientific Title

Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Silexan (WS®1265) in patients with mixed anxiety and depressive disorder

#### **Study objectives**

The objective of the study is to prove the efficacy of Silexan (WS®1265) in the treatment of patients with mixed anxiety and depressive disorder in comparing the change of the HAMA total score and the MADRS total score between baseline and Week 10 between Silexan and placebo.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethik-Kommission bei der Medizinischen Fakultät der Universität Würzburg, 14 September 2012 ref: 180/12 ff

# Study design

Multi-center double-blind placebo-controlled randomized phase IIIb study

# Primary study design

Interventional

# Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Mixed anxiety and depressive disorder

#### **Interventions**

80 mg/day Silexan or placebo for 70 days

#### Intervention Type

Other

#### **Phase**

Phase III

#### Primary outcome(s)

The change of the HAMA total score and the MADRS total score

#### Key secondary outcome(s))

- 1. Response criteria (50 % reduction; remission) based on the HAMA total score and on the MADRS total score
- 2. Items 2 (tension) and 14 (behaviour at interview) of the HAMA, change and response
- 3. Single items and subscores of the Hamilton Rating Scale for Anxiety
- 4. Single items of the MADRS
- 5. State-Trait Anxiety Inventory (STAI)
- 6. Total score, subscores state anxiety and trait anxiety, early improvement on day 3
- 7. Subscales of the Sheehan Disability Scale (SDS) and subscores of the SF-36
- 8. Clinical Global Impressions
- 9. Hospital Anxiety and Depression Scale (HADS), total score change, subscore depression and subscore anxiety

#### Completion date

31/12/2013

# **Eligibility**

#### Key inclusion criteria

- 1. Diagnosis of mixed anxiety and depressive disorder (ICD-10, F41.2)
- 2. Age 18 to 65 years
- 3. HAMA total score  $\geq$  18 with item 1 anxious mood  $\geq$  2 (moderate) and item 6 depressed mood  $\geq$
- 2 (moderate)
- 4. BMI between 18 and 29.9 kg/m2
- 5. Written informed consent

### Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

#### Lower age limit

18 years

#### Sex

All

#### Key exclusion criteria

- 1. Any clinically important psychiatric or neurological diagnoses, other than study indication, within 6 month before the study
- 2. Risk of suicide (MADRS item  $10 \ge 2$  during study) or previous suicide attempt or clear display of auto-aggressive behaviour
- 3. History or evidence of alcohol and/or substance abuse or dependence
- 4. Current use of other psychotropic drugs within 30 days before baseline visit
- 5. History of hypersensitivity to Lavender preparations
- 6. Any unstable acute medical disorder
- 7. Unacceptability to discontinue or likelihood to need medication during the study that is prohibited as concomitant treatment
- 8. Non-medical psychiatric treatment during the course of the study
- 9. Clinical significant abnormality of ECG and/or laboratory values
- 10. Pregnancy, lactation

#### Date of first enrolment

29/10/2012

#### Date of final enrolment

31/12/2013

# Locations

#### Countries of recruitment

Germany

# Study participating centre Bezirk Unterfranken

Werneck Germany 97444

# **Sponsor information**

#### Organisation

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

#### **ROR**

https://ror.org/043rrkc78

# Funder(s)

# Funder type

#### Funder Name

Dr. Willmar Schwabe GmbH & Co. (Germany)

# **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes